Recombinant Human BCMA (Highly Pure)

<strong>Recombinant Human BCMA</strong>_x000D_ <strong>Catalog number:</strong> B2010342_x000D_ <strong>Lot number:</strong> Batch Dependent_x000D_ <strong>Expiration Date:</strong> Batch dependent_x000D_ <strong>Volume/Weight:</strong> 10 ug_x000D_ <strong>pH:</strong> 7.4 upon reconstitution_x000D_ <strong>Supplied as:</strong> Lyophilized Powder_x000D_ <strong>Appearance:</strong> Powder_x000D_ <strong>Applications:</strong> highly pure Recombinant Human BCMA expressed in E. coli. This protein acts as a member of tumor necrosis factor receptor superfamily that promotes B-cell survival and plays a role in the regulation of humoral immunity._x000D_ <strong>Storage:</strong> -20C_x000D_ <strong>Keywords:</strong> rHuBCMA; TNFRSF17; CD269; B-cell maturation protein; BCM_x000D_ <strong>Grade:</strong> Biotechnology grade. All components are highly pure (minimum 95%). All solutions are made with Type I ultrapure water (resistivity &gt;18 MΩ-cm) and are filtered through 0.22 um._x000D_ _x000D_ <strong>References:</strong>_x000D_ 1: Yu B, Jiang T, Liu D. BCMA-targeted immunotherapy for multiple myeloma. J_x000D_ Hematol Oncol. 2020 Sep 17;13(1):125._x000D_ _x000D_ 2: D'Agostino M, Raje N. Anti-BCMA CAR T-cell therapy in multiple myeloma: can_x000D_ we do better? Leukemia. 2020 Jan;34(1):21-34._x000D_ _x000D_ 3: Gavriatopoulou M, Ntanasis-Stathopoulos I, Dimopoulos MA, Terpos E. Anti-BCMA_x000D_ antibodies in the future management of multiple myeloma. Expert Rev Anticancer_x000D_ Ther. 2019 Apr;19(4):319-326._x000D_ _x000D_ 4: Tai YT, Anderson KC. B cell maturation antigen (BCMA)-based immunotherapy for_x000D_ multiple myeloma. Expert Opin Biol Ther. 2019 Nov;19(11):1143-1156._x000D_ PMC6785394._x000D_ _x000D_ 5: Cho SF, Anderson KC, Tai YT. Targeting B Cell Maturation Antigen (BCMA) in_x000D_ Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy. Front Immunol._x000D_ 2018 Aug 10;9:1821._x000D_ _x000D_ 6: Shah N, Chari A, Scott E, Mezzi K, Usmani SZ. B-cell maturation antigen_x000D_ (BCMA) in multiple myeloma: rationale for targeting and current therapeutic_x000D_ approaches. Leukemia. 2020 Apr;34(4):985-1005._x000D_ _x000D_ 7: Raje N, Berdeja J, Lin Y, Siegel D, Jagannath S, Madduri D, Liedtke M,_x000D_ Rosenblatt J, Maus MV, Turka A, Lam LP, Morgan RA, Friedman K, Massaro M, Wang_x000D_ J, Russotti G, Yang Z, Campbell T, Hege K, Petrocca F, Quigley MT, Munshi N,_x000D_ Kochenderfer JN. Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory_x000D_ Multiple Myeloma. N Engl J Med. 2019 May 2;380(18):1726-1737._x000D_ _x000D_ 8: Pont MJ, Hill T, Cole GO, Abbott JJ, Kelliher J, Salter AI, Hudecek M,_x000D_ Comstock ML, Rajan A, Patel BKR, Voutsinas JM, Wu Q, Liu L, Cowan AJ, Wood BL,_x000D_ Green DJ, Riddell SR. γ-Secretase inhibition increases efficacy of BCMA-specific_x000D_ chimeric antigen receptor T cells in multiple myeloma. Blood. 2019 Nov_x000D_ 7;134(19):1585-1597._x000D_ _x000D_ 9: Cho SF, Lin L, Xing L, Li Y, Yu T, Anderson KC, Tai YT. BCMA-Targeting_x000D_ Therapy: Driving a New Era of Immunotherapy in Multiple Myeloma. Cancers_x000D_ (Basel). 2020 Jun 5;12(6):1473._x000D_ <a href="https://pubmed.ncbi.nlm.nih.gov/32471019/">10: Feng D, Sun J. Overview of anti-BCMA CAR-T immunotherapy for multiple_x000D_ myeloma and relapsed/refractory multiple myeloma. Scand J Immunol. 2020_x000D_ Aug;92(2):e12910. </a>_x000D_ _x000D_ <strong>Products Related to Recombinant Human BCMA </strong> <a href="https://moleculardepot.com/product-category/Proteins/">: Proteins</a>